Plonmarlimab
Sponsors
TJ Biopharma Co., Ltd.
Conditions
Acute Gouty ArthritisHemophagocytic LymphohistiocytosesRelapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
Phase 2
A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))
CompletedNCT07034209
Start: 2023-04-07End: 2025-04-18Updated: 2025-06-24
A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis
RecruitingNCT07453004
Start: 2026-03-26End: 2027-12-31Target: 170Updated: 2026-04-03